Profile data is unavailable for this security.
About the company
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.
- Revenue in USD (TTM)55.89k
- Net income in USD-7.99m
- Incorporated1999
- Employees12.00
- LocationSonnet Biotherapeutics Holdings Inc100 Overlook Center, Suite 102PRINCETON 08540United StatesUSA
- Phone+1 (609) 375-2227
- Fax+1 (302) 636-5454
- Websitehttps://www.sonnetbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peak Bio Inc | 354.02k | -4.63m | 1.62m | -- | -- | -- | -- | 4.57 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Trevena Inc | 443.00k | -37.03m | 1.62m | 23.00 | -- | -- | -- | 3.67 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Hi-Great Group Holding Co | 69.41k | -54.82k | 1.78m | -- | -- | -- | -- | 25.64 | -0.0005 | -0.0005 | 0.0007 | -0.0014 | 0.7459 | 0.6517 | -- | -- | -58.91 | -- | -- | -- | 54.26 | -- | -78.98 | -- | 0.0276 | -15.03 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Aclarion Inc | 53.95k | -5.90m | 1.90m | 6.00 | -- | 0.945 | -- | 35.19 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -12.82m | 1.91m | 5.00 | -- | 0.0795 | -- | -- | -2,217.58 | -2,217.58 | 0.00 | 16.98 | 0.00 | -- | -- | 0.00 | -52.54 | -- | -110.73 | -- | -- | -- | -- | -- | -- | -- | 0.0626 | -- | -- | -- | 3.02 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 1.92m | 51.00 | -- | -- | -- | 0.0960 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -9.82m | 2.09m | 8.00 | -- | 0.2893 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -6.46m | 2.16m | 2.00 | -- | 0.4049 | -- | -- | -12.64 | -12.64 | 0.00 | 3.70 | 0.00 | -- | -- | 0.00 | -82.83 | -69.27 | -119.83 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.00 | -- | -- | -- | 60.32 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 55.89k | -7.99m | 2.17m | 12.00 | -- | 0.8297 | -- | 38.75 | -24.17 | -24.17 | 0.1156 | 4.01 | 0.0071 | -- | 0.0881 | 4,657.50 | -100.88 | -- | -255.30 | -- | -- | -- | -14,287.67 | -- | -- | -331.07 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Qrons Inc | 0.00 | -860.04k | 2.18m | 2.00 | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.088 | 0.00 | -- | -- | 0.00 | -9,368.63 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -9.21 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 2.36m | 62.00 | -- | 0.3314 | -- | 0.0925 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -8.68m | 2.54m | 8.00 | -- | 0.3989 | -- | -- | -23.77 | -23.77 | 0.00 | 7.40 | 0.00 | -- | -- | 0.00 | -98.62 | -71.92 | -126.86 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Halberd Corp | 281.24k | 25.34k | 2.54m | 3.00 | 1.72 | -- | 100.26 | 9.04 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| GRI Bio Inc | 0.00 | -8.28m | 2.56m | 4.00 | -- | 0.1487 | -- | -- | -100.69 | -100.69 | 0.00 | 5.88 | 0.00 | -- | -- | 0.00 | -130.64 | -192.93 | -187.01 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.40m | 2.68m | 1.00 | -- | 3.38 | -- | -- | -1.45 | -1.45 | 0.00 | 0.1774 | 0.00 | -- | -- | 0.00 | -152.72 | -74.49 | -206.36 | -92.56 | -- | -- | -- | -- | -- | -17.09 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -8.88m | 2.72m | 2.00 | -- | 0.3877 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Sonnet Biotherapeutics Holdings Inc's reporting currency: US Dollar USD
11.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 34.00k | 5.23% |
| Sabby Management LLCas of 30 Jun 2024 | 29.80k | 4.58% |
| Virtu Americas LLCas of 30 Jun 2024 | 4.09k | 0.63% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.09k | 0.32% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.84k | 0.28% |
| Tower Research Capital LLCas of 30 Jun 2024 | 896.00 | 0.14% |
| UBS Securities LLCas of 30 Jun 2024 | 500.00 | 0.08% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 65.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 3.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 1.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
